This site is intended for healthcare professionals

Jardiance reduced the risk of first plus recurrent cardiovascular events in type 2 diabetes and CV disease in a new analysis from the EMPA-REG OUTCOME trial.- Eli Lilly

Read time: 2 mins
Last updated:19th Nov 2020
Published:19th Nov 2020
Condition: Diabetes Type 2 + CV Disease
Type: drug
Register free for full access to